Carbomix

Primær information

  • Handelsnavn:
  • Carbomix granulat til oral suspension
  • Lægemiddelform:
  • granulat til oral suspension
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

Lokation

  • Fås i:
  • Carbomix granulat til oral suspension
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisationsnummer:
  • 60440
  • Sidste ændring:
  • 22-02-2018

Produktresumé

5. februar 2018

PRODUKTRESUMÉ

for

Carbomix, granulat til oral suspension (Orifarm)

0.

D.SP.NR.

9660

1.

LÆGEMIDLETS NAVN

Carbomix, granulat til oral suspension

2.

KVALITATIV OG KVANTITATIV SAMMENSÆTNING

Hver flaske indeholder 50 g aktivt kul. Efter opløsning i vand indeholder produktet ca.

12,5 g aktivt kul pr. 100 ml homogen opløsning.

Alle hjælpestoffer er anført under pkt. 6.1.

3.

LÆGEMIDDELFORM

Granulat til oral suspension (Orifarm).

4.

KLINISKE OPLYSNINGER

4.1

Terapeutiske indikationer

Ved akut oral forgiftning og overdosering af medicinske produkter

4.2

Dosering og indgivelsesmåde

Voksne og børn over 12 år:

50-100 g aktivt kul (= 1-2 flasker Carbomix) indtages så hurtigt som muligt. Ved alvorlige

forgiftninger fortsættes behandlingen i et par dage med en dosis på 20 g hver 4-6 time (20

g aktivt kul svarer ca. til 160 ml af suspensionen).

Børn under 12 år:

Anbefalet dosis: ca. 1 g aktivt kul pr. kg legemsvægt.

I tilfælde af akut forgiftning hos børn under 12 år gives halv voksendosis (= 1/2 flaske). Til

børn under 4 år startes med en dosis på 1/4 flaske, hvilket gentages flere gange i samråd

med lægen.

Ved bevidstløse patienter skal en læge, eller en sygeplejerske under lægetilsyn, give

suspensionen ved hjælp af en sonde.

60440_spc.doc

Side 1 af 5

Carbomix kan også gives efter opkastning eller maveskylning.

For at modvirke optagelse af giftstoffer i kroppen og for at fjerne de allerede absorberede

giftstoffer er det vigtigt, at Carbomix indtages hurtigt. Dog kan langsom indtagelse også

have en positiv virkning.

Ved alvorlig forgiftning anbefales det at indtage flere doser aktivt kul.

Tilberedelse af suspension:

Ryst flasken grundigt for at løsne granulatet. Tilsæt vand til flaskens røde streg. Ryst

grundigt i 1 minut. Herved fås ca. 400 ml suspension. Flasken åbnes forsigtigt og indholdet

indtages omgående. Hvis indholdet indtages ad flere gange, skal flasken rystes for hver

gang.

Flasken er udstyret med en speciel top, der kan bruges ved hurtig og direkte

sondetilslutning. Toppen løsnes forsigtigt for at frigøre evt. tryk i flasken og lukkes igen.

Derefter skæres toppen af inden sondetilslutning.

4.3

Kontraindikationer

Overfølsomhed over for det aktive stof eller et eller flere af hjælpestofferne anført i pkt. 6.

Carbomix må ikke anvendes, hvis forgiftningen helt sikkert skyldes ætsende stoffer (f.eks.

stærke syrer eller baser), da det i sådanne tilfælde kan vanskeliggøre oesofagoskopi og

gastroskopi.

4.4

Særlige advarsler og forsigtighedsregler vedrørende brugen

Ved akut oral forgiftning og overdosering af medicin skal der omgående tages kontakt til

læge eller giftcenter. Umiddelbart derefter indtages Carbomix suspensionen i henhold til

forskrifterne.

Aktivt kul adsorberer ikke organiske og uorganiske salte og opløsninger dvs. salte i jern-,

lithium-, thallium-, cyanid-, methanol-, ethanol-, ethylenglykol- og petroleumsholdige

opløsninger. I tilfælde af forgiftning med sådanne stoffer skal anden form for afgiftning

foretages (f.eks. maveskylning). De mest almindelige forgiftninger af denne type er angivet

nedenfor med den for disse stoffer relevante behandling:

Specific antidote:

Cyanid

Natriumnitrit/4-dimethylaminfenol

Jernforbindelser

Deferoxamin

Lithium

Kalciumpolystyrensulfonat

Methanol

Ethanol

Ethylenglykol

Ethanol

Ved mange typer forgiftning skal der ud over Carbomix indtages en bestemt modgift

(f.eks. ved paracetamolforgiftning: acetylcystein).

Når oral behandling eller en bestemt, oral modgift er meget vigtig for patienten, frarådes

indtagelse af aktivt kul.

Indtagelse af aktivt kul frarådes for patienter, der tager anti-peristaltisk medicin, eller der

har indtaget et giftstof med anti-peristaltisk virkning, pga. risiko for paralytisk ileus,

hvilket kan medføre tarmperforering (se 4.3).

60440_spc.doc

Side 2 af 5

Aktivt kul giver sort afføring.

4.5

Interaktion med andre lægemidler og andre former for interaktion

Indtagelse af aktivt kul vil normalt nedsætte virkningen af andre orale præparater pga.

virkningsforløbet.

Samtidig indtagelse af furosemide og aktivt kul har vist sig at resultere i en stor reduktion

af virkningen af furosemide.

Indtagelse af aktivt kul kan også reducere virkningen af ægløsningshæmmende medicin (se

4.6)

4.6

Graviditet og amning

Kvinder med risiko for graviditet / Svangerskabsforebyggelse

Aktivt kul kan nedsætte virkningen af p-piller. Derfor anbefales det at anvende alternativ,

effektiv og sikker prævention under behandlingen.

Graviditet

Aktivt kul kan, ifølge tidligere erfaringer, anvendes som foreskrevet uden risiko for

fosteret.

Amning

Aktivt kul kan, ifølge tidligere erfaringer, anvendes som foreskrevet uden risiko for barnet.

4.7

Virkninger på evnen til at føre motorkøretøjer eller betjene maskiner

Carbomix påvirker ikke køre- eller maskinbetjeningsevnen.

4.8

Bivirkninger

De fleste rapporterede bivirkninger i forbindelse med indtagelse af aktivt kul relaterer til

mavetarmsystemet. De fleste af disse kan dog også skyldes tilgrundliggende

omstændigheder.

Hændelsesfrekvensen kendes ikke (kan ikke vurderes ud fra forhåndenværende data).

Almindeligt rapporterede bivirkninger er: opkastning, forstoppelse, mavesmerter, diarré,

kvalme, pludselig afføringstrang, anal irritation.

Der har været enkelte rapporter (alle som følge af indtagelse af gentagne høje doser af

aktivt kul) om: (pseudo)forstoppelse af tyndtarmen, der har krævet operation og om hård

afføring med perforering af tyktarmen til følge (se 4.9)

Indberetning af formodede bivirkninger

Når lægemidlet er godkendt, er indberetning af formodede bivirkninger

vigtig. Det muliggør løbende overvågning af benefttriikkforholdet for

lægemidlet. Læger og iundhediperionale anmodei om at indberette

alle formodede bivirkninger via:

Lægemiddelityrelien

Axel Heidei Gade 1

DKk2300 København S

Webited: www.meldenbivirkning.dk

Ekmail: dkma@dkma.dk

4.9

Overdosering

60440_spc.doc

Side 3 af 5

Der kan opstå forstoppelse af tyndtarmen ved gentagen overdosering af medicinsk kul.

Dette kan undgå ved at indtage afføringsmiddel (f.eks. natriumsulfat).

4.3

Udlevering

5.

FARMAKOLOGISKE EGENSKABER

5.0

Terapeutisk klassifikation

Antidot, aktivt kul: ATC-kode: A 07 BA 01

5.1

Farmakodynamiske egenskaber

Farmakodynamisk gruppe: medicinsk kul.

ATC-kode: A07BA01.

Aktivt kul er et specielt carboniseret materiale baseret på plantestoffer og med en stor

indvendig overflade, som kan adsorbere skadelige, uønskede og sygdomsfremkaldende

stoffer i mavetarmkanalen. Ved forgiftning kan aktivt kul adsorbere de aktive stoffer fra

mavetarmkanalen.

Adsorbering i aktivt kul af et delvist optaget aktivt stof giver koncentrationsfald

mellem cirkulerende plasma og tarmindhold. Derfor kan passivt adsorberende stoffer på ny

diffundere i modsat retning mod tarmen. Herved kan gentagen indtagelse af aktivt kul også

være virksom efter indtagelse af et aktivt stof.

5.2

Farmakokinetiske egenskaber

Da aktivt kul ikke optages i mavetarmkanalen, opstår der ikke nogen distributionsfase eller

metabolisme.

Aktivt kul er et lokalt virkende middel, som efter oral indtagelse kan adsorbere opløste

aktive stoffer i mavetarmkanalen. Derfor skal det indtages så hurtigt som muligt i tilfælde

af indtagelse af giftstoffer eller medicinoverdosis.

For at modvirke desorption af adsorberende giftstoffer er det vigtigt, at det aktive kul

passerer hurtigst muligt gennem mavetarmkanalen, f.eks. ved at give et osmotisk laksantia

(natriumsulfat).

5.3

Prækliniske sikkerhedsdata

De prækliniske data viser ingen særlig fare for mennesker.

6.

FARMACEUTISKE OPLYSNINGER

6.1

Hjælpestoffer

Citronsyre-monohydrat, Glycerol, Acacia gummi

6.2

Uforligeligheder

Ikke relevant.

6.3

Opbevaringstid

5 år.

Færdig suspension: 3 dage.

60440_spc.doc

Side 4 af 5

6.4

Særlige opbevaringsforhold

Inden opblanding skal granulatet opbevares tørt.

Efter opblanding skal blandingen opbevares i køleskab (2

C - 8

6.5

Emballagetyper og pakningsstørrelser

HDPE-flaske med HDPE-skruelåg.

6.6

Regler for destruktion og anden håndtering

Ingen særlige krav.

7.

INDEHAVER Af MARKEDSFØRINGSTILLADELSEN

Orifarm A/S

Energivej 15

5260 Odense S

8.

MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE)

60440

9.

DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE

5. februar 2018

10.

DATO FOR ÆNDRING AF TEKSTEN

60440_spc.doc

Side 5 af 5

  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.



  • Dokumenter på andre sprog er tilgængelige her

17-4-2018

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Overland Park, KS, Epic Products, LLC is voluntarily recalling all lots of Euphoric capsules, packaged in 1 count blister cards, 3 count bottles, and 12 count bottles to the consumer level. FDA analysis found samples of Euphoric to be tainted with undeclared sildenafil and tadalafil, active ingredients in two FDA-approved prescription drug products, also known as phosphodiesterase 5-inhibitors (PDE-5 inhibitors), used to treat male erectile dysfunction (ED). The presence of sildenafil and tadalafil in E...

FDA - U.S. Food and Drug Administration

16-4-2018

Women taking birth control pills reminded to return any packages for replacement if the pills are missing or look unusual

Women taking birth control pills reminded to return any packages for replacement if the pills are missing or look unusual

In light of continuing complaints of quality issues involving certain prescription birth control pills, Health Canada is reminding women to check their packages of birth control pills. If you notice anything unusual in the package, such as missing or damaged pills, you should return the package to the pharmacy for replacement as soon as possible. Skipping a dose because the pill is missing, or taking a damaged (for example, chipped or fragmented) pill, may increase the risk of pregnancy because less acti...

Health Canada

14-4-2018

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

AMA Wholesale Inc. (Distributor/Re-seller), is voluntarily recalling Rhino 69 Extreme 50000 capsules to the consumer level. FDA analysis found the product to be tainted with undeclared tadalafil. Tadalafil is an active ingredient in a FDA-approved prescription drug that is used for erectile dysfunction.

FDA - U.S. Food and Drug Administration

10-7-2018

Raloxifene Teva (Teva B.V.)

Raloxifene Teva (Teva B.V.)

Raloxifene Teva (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2017)4939 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2013 (Roche Registration Limited)

EU/3/18/2013 (Roche Registration Limited)

EU/3/18/2013 (Active substance: Polatuzumab vedotin) - Orphan designation - Commission Decision (2018)2409 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/231/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (Active substance: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII) - Orphan designation - Commission Decision (2018)2408 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2011 (Ultragenyx Germany GmbH)

EU/3/18/2011 (Ultragenyx Germany GmbH)

EU/3/18/2011 (Active substance: Burosumab) - Orphan designation - Commission Decision (2018)2407 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/026/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2010 (Novartis Europharm Limited)

EU/3/18/2010 (Novartis Europharm Limited)

EU/3/18/2010 (Active substance: Branaplam) - Orphan designation - Commission Decision (2018)2406 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/249/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2009 (SOTIO a.s)

EU/3/18/2009 (SOTIO a.s)

EU/3/18/2009 (Active substance: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo) - Orphan designation - Commission Decision (2018)2405 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/246/17

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)

EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)

EU/3/18/2008 (Active substance: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1) - Orphan designation - Commission Decision (2018)2404 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/254/17

Europe -DG Health and Food Safety

18-4-2018

Melatonin (haemorrhage) (Therapicon Srl)

Melatonin (haemorrhage) (Therapicon Srl)

Melatonin (haemorrhage) (Active substance: Melatonin) - Refusal of orphan designation - Commission Decision (2018)2410 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/127/17

Europe -DG Health and Food Safety

17-4-2018

Sialanar (Proveca Limited)

Sialanar (Proveca Limited)

Sialanar (Active substance: glycopyrronium bromide) - Centralised - Yearly update - Commission Decision (2018)2340 of Tue, 17 Apr 2018

Europe -DG Health and Food Safety

17-4-2018

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Active substance: Ornithine phenylacetate) - Transfer of orphan designation - Commission Decision (2018)2355 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/105/11/T/03

Europe -DG Health and Food Safety

17-4-2018

PritorPlus (Bayer AG)

PritorPlus (Bayer AG)

PritorPlus (Active substance: Telmisartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2342 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/414/T/115

Europe -DG Health and Food Safety

17-4-2018

Pritor (Bayer AG)

Pritor (Bayer AG)

Pritor (Active substance: telmisartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2344 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/210/T/124

Europe -DG Health and Food Safety

17-4-2018

Autologous skeletal myoblasts expanded ex vivo (Assistance Publique - Hopitaux de Paris (APHP))

Autologous skeletal myoblasts expanded ex vivo (Assistance Publique - Hopitaux de Paris (APHP))

Autologous skeletal myoblasts expanded ex vivo (Active substance: Autologous skeletal myoblasts expanded ex vivo) - Refusal of orphan designation - Commission Decision (2018)2354 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/144/17

Europe -DG Health and Food Safety

17-4-2018

Clevor (Orion Corporation)

Clevor (Orion Corporation)

Clevor (Active substance: Ropinirole) - Centralised - Authorisation - Commission Decision (2018)2338 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4417

Europe -DG Health and Food Safety

17-4-2018

Bretaris Genuair (AstraZeneca AB)

Bretaris Genuair (AstraZeneca AB)

Bretaris Genuair (Active substance: aclidinium bromide) - Centralised - Yearly update - Commission Decision (2018)2345 of Tue, 17 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Kinzalkomb (Bayer AG)

Kinzalkomb (Bayer AG)

Kinzalkomb (Active substance: Telmisartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2294 of Mon, 16 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/415/T/105

Europe -DG Health and Food Safety

16-4-2018

Lumigan (Allergan Pharmaceuticals Ireland)

Lumigan (Allergan Pharmaceuticals Ireland)

Lumigan (Active substance: Bimatoprost) - Centralised - Yearly update - Commission Decision (2018)2300 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Ravicti (Horizon Pharma Ireland Limited)

Ravicti (Horizon Pharma Ireland Limited)

Ravicti (Active substance: Glycerol phenylbutyrate) - Centralised - Yearly update - Commission Decision (2018)2302 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Actrapid (Novo Nordisk A/S)

Actrapid (Novo Nordisk A/S)

Actrapid (Active substance: Insulin human (rDNA)) - Centralised - Yearly update - Commission Decision (2018)2301 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Vidaza (Celgene Europe Limited)

Vidaza (Celgene Europe Limited)

Vidaza (Active substance: Azacitidine) - Centralised - Yearly update - Commission Decision (2018)2305 of Mon, 16 Apr 2018

Europe -DG Health and Food Safety

16-4-2018

Signifor (Novartis Europharm Limited)

Signifor (Novartis Europharm Limited)

Signifor (Active substance: pasireotide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2304 of Mon, 16 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2052/T/37

Europe -DG Health and Food Safety

13-4-2018

Zulvac 8 Ovis (Zoetis Belgium S.A.)

Zulvac 8 Ovis (Zoetis Belgium S.A.)

Zulvac 8 Ovis (Active substance: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* = 1) - Centralised - Yearly update - Commission Decision (2018)2244 of Fri, 13 Apr 2018

Europe -DG Health and Food Safety

10-4-2018

Kineret (Swedish Orphan Biovitrum AB (publ))

Kineret (Swedish Orphan Biovitrum AB (publ))

Kineret (Active substance: Anakinra) - Centralised - 2-Monthly update - Commission Decision (2018)2188 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/363/II/56

Europe -DG Health and Food Safety

10-4-2018

Tamiflu (Roche Registration GmbH)

Tamiflu (Roche Registration GmbH)

Tamiflu (Active substance: Oseltamivir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2185 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/402/T/131

Europe -DG Health and Food Safety

10-4-2018

Zelboraf (Roche Registration GmbH)

Zelboraf (Roche Registration GmbH)

Zelboraf (Active substance: vemurafenib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2184 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2409/T/47

Europe -DG Health and Food Safety

10-4-2018

Stronghold Plus (Zoetis Belgium S.A.)

Stronghold Plus (Zoetis Belgium S.A.)

Stronghold Plus (Active substance: selamectin / sarolaner) - Centralised - Yearly update - Commission Decision (2018)2164 of Tue, 10 Apr 2018

Europe -DG Health and Food Safety

10-4-2018

Tarceva (Roche Registration GmbH)

Tarceva (Roche Registration GmbH)

Tarceva (Active substance: Erlotinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2186 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/618/T/57

Europe -DG Health and Food Safety

10-4-2018

Apoquel (Zoetis Belgium S.A.)

Apoquel (Zoetis Belgium S.A.)

Apoquel (Active substance: Oclacitinib maleate) - Centralised - Yearly update - Commission Decision (2018)2165 of Tue, 10 Apr 2018

Europe -DG Health and Food Safety

10-4-2018

Fuzeon (Roche Registration GmbH)

Fuzeon (Roche Registration GmbH)

Fuzeon (Active substance: Enfuvirtide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2181 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/514/T/50

Europe -DG Health and Food Safety

10-4-2018

Herceptin (Roche Registration GmbH)

Herceptin (Roche Registration GmbH)

Herceptin (Active substance: trastuzumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2180 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/278/T/142

Europe -DG Health and Food Safety

10-4-2018

RoActemra (Roche Registration GmbH)

RoActemra (Roche Registration GmbH)

RoActemra (Active substance: tocilizumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2179 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/955/T/75

Europe -DG Health and Food Safety

10-4-2018

Gazyvaro (Roche Registration GmbH)

Gazyvaro (Roche Registration GmbH)

Gazyvaro (Active substance: obinutuzumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2178 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2799/T/24

Europe -DG Health and Food Safety

10-4-2018

Revolade (Novartis Europharm Limited)

Revolade (Novartis Europharm Limited)

Revolade (Active substance: Eltrombopag) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2182 of Tue, 10 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1110/T/47

Europe -DG Health and Food Safety

6-4-2018

Bonviva (Atnahs Pharma UK Limited)

Bonviva (Atnahs Pharma UK Limited)

Bonviva (Active substance: Ibandronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2137 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/501/T/64

Europe -DG Health and Food Safety

6-4-2018

Kinzalmono (Bayer AG)

Kinzalmono (Bayer AG)

Kinzalmono (Active substance: telmisartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2138 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/211/T/111

Europe -DG Health and Food Safety

6-4-2018

Marixino (KRKA, d.d., Novo mesto)

Marixino (KRKA, d.d., Novo mesto)

Marixino (Active substance: Memantine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2136 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2658/T/13

Europe -DG Health and Food Safety

6-4-2018

Convenia (Zoetis Belgium S.A.)

Convenia (Zoetis Belgium S.A.)

Convenia (Active substance: Cefovecin) - Centralised - Yearly update - Commission Decision (2018)2126 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 1 Bovis (Zoetis Belgium S.A.)

Zulvac 1 Bovis (Zoetis Belgium S.A.)

Zulvac 1 Bovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP = 1) - Centralised - Yearly update - Commission Decision (2018)2127 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 1 Ovis (Zoetis Belgium S.A.)

Zulvac 1 Ovis (Zoetis Belgium S.A.)

Zulvac 1 Ovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP = 1) - Centralised - Yearly update - Commission Decision (2018)2128 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 8 Bovis (Zoetis Belgium S.A.)

Zulvac 8 Bovis (Zoetis Belgium S.A.)

Zulvac 8 Bovis (Active substance: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* = 1) - Centralised - Yearly update - Commission Decision (2018)2129 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Stronghold (Zoetis Belgium S.A.)

Stronghold (Zoetis Belgium S.A.)

Stronghold (Active substance: Selamectin) - Centralised - Yearly update - Commission Decision (2018)2125 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Bondronat (Atnahs Pharma UK Limited)

Bondronat (Atnahs Pharma UK Limited)

Bondronat (Active substance: Ibandronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2135 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/101/T/79

Europe -DG Health and Food Safety

6-4-2018

Esbriet (Roche Registration GmbH)

Esbriet (Roche Registration GmbH)

Esbriet (Active substance: Pirfenidone) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2132 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2154/T/52

Europe -DG Health and Food Safety

6-4-2018

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Active substance: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor) - Transfer of orphan designation - Commission Decision (2018)2008 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/160/11/T/01

Europe -DG Health and Food Safety

3-4-2018

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (AbbVie Deutschland GmbH and Co. KG)

EU/3/12/1080 (Active substance: 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) - Transfer of orphan designation - Commission Decision (2018)2056 of Tue, 03 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/124/12/T/01

Europe -DG Health and Food Safety

29-3-2018

Versican Plus DHPPi/L4R (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4R (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4R (Active substance: Vaccine against CDV, CAV-2, CPV, CPIV, Leptospirosis and Rabies.) - Centralised - Yearly update - Commission Decision (2018)2060 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac SBV (Zoetis Belgium S.A.)

Zulvac SBV (Zoetis Belgium S.A.)

Zulvac SBV (Active substance: Inactivated Schmallenberg virus, strain BH80/11-4) - Centralised - Yearly update - Commission Decision (2018)2057 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Ganfort (Allergan Pharmaceuticals Ireland)

Ganfort (Allergan Pharmaceuticals Ireland)

Ganfort (Active substance: bimatoprost / timolol) - Centralised - Yearly update - Commission Decision (2018)2055 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Active substance: Vaccine against canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza-2 virus and leptospirosis) - Centralised - Yearly update - Commission Decision (2018)2059 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Versican Plus DHPPi (Zoetis Belgium S.A.)

Versican Plus DHPPi (Zoetis Belgium S.A.)

Versican Plus DHPPi (Active substance: Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza type 2 virus) - Centralised - Yearly update - Commission Decision (2018)2058 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac 1+8 Ovis (Zoetis Belgium S.A.)

Zulvac 1+8 Ovis (Zoetis Belgium S.A.)

Zulvac 1+8 Ovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 / Inactivated Bluetongue Virus, serotype 8, strain BTV-8/BEL2006/02) - Centralised - Yearly update - Commission Decision (2018)2061 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac 1+8 Bovis (Zoetis Belgium S.A.)

Zulvac 1+8 Bovis (Zoetis Belgium S.A.)

Zulvac 1+8 Bovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 / Inactivated Bluetongue Virus, serotype 8, strain BTV-8/BEL2006/02) - Centralised - Yearly update - Commission Decision (2018)2062 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

A Few Tips to Make for a More Active You

A Few Tips to Make for a More Active You

Title: A Few Tips to Make for a More Active YouCategory: Health NewsCreated: 3/28/2018 12:00:00 AMLast Editorial Review: 3/28/2018 12:00:00 AM

US - MedicineNet

28-3-2018

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Roche Registration GmbH)

EU/3/04/241 (Active substance: Pirfenidone) - Transfer of orphan designation - Commission Decision (2018)2006 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/OD/052/04/T/03

Europe -DG Health and Food Safety

28-3-2018

EU/3/10/803 (Astellas Pharma Europe B.V.)

EU/3/10/803 (Astellas Pharma Europe B.V.)

EU/3/10/803 (Active substance: Chimeric monoclonal antibody against claudin-18 splice variant 2) - Transfer of orphan designation - Commission Decision (2018)2007 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/083/10/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/13/1177 (Astellas Pharma Europe B.V.)

EU/3/13/1177 (Astellas Pharma Europe B.V.)

EU/3/13/1177 (Active substance: Chimeric monoclonal antibody against claudin-18 splice variant 2) - Transfer of orphan designation - Commission Decision (2018)2010 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/071/13/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/12/1092 (Astellas Pharma Europe B.V.)

EU/3/12/1092 (Astellas Pharma Europe B.V.)

EU/3/12/1092 (Active substance: Chimeric monoclonal antibody against claudin 6) - Transfer of orphan designation - Commission Decision (2018)2009 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/147/12/T/01

Europe -DG Health and Food Safety

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety